&
The platelet-activating factor (PAF) antagonist lexipafant has a role in the treatment of acute pancreatitis, according to research findings presented at the 5th International Congress on Platelet-Activating Factor and Related Lipid Mediators [ Berlin, Germany; September 1995 ]. The therapeutic potential of PAF antagonists is currently under investigation in several indications, particularly inflammatory diseases. Few convincing findings on the therapeutic value of these agents have been presented to date, but the latest data are encouraging.
This is a preview of subscription content, log in via an institution to check access.
Rights and permissions
About this article
Cite this article
Schwarz, T. Lexipafant - a glimmer of hope for pancreatitis. Inpharma Wkly. 1007, 3–4 (1995). https://doi.org/10.2165/00128413-199510070-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-199510070-00003